News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Pharma and Teva Pharmaceutical Industries Limited (TEVA) Announce First License Agreement for Sitavig® for Israel


6/13/2012 10:37:22 AM

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to oncology orphan products and specialty products today announces the signature of an exclusive license agreement for Sitavig® (Acyclovir Lauriad™) with Abic Marketing Limited ("Teva"), a group subsidiary of Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) for commercialization rights in Israel.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES